Johnson & Johnson Pharmaceutical Business Review Transcript
Welcome to the Johnson & Johnson 2021 Business Review Meeting, Highlighting Pharmaceuticals.
Please note that today's presentation includes forward-looking statements. We encourage you to review the cautionary statement included in today's presentation, which identify certain factors that may cause the company's actual results to differ materially from those projected. Our SEC filings, along with reconciliations of any non-GAAP financial measures utilized to the most comparable GAAP measures, are also available at investor.jnj.com.
Additionally, several of the products and compounds discussed today are being developed in collaboration with strategic partners or licensed from other companies. These slides acknowledge those relationships.
Ladies and gentlemen, please welcome Vice President of Investor Relations, Jessica Moore.
Good morning, everyone, or good afternoon, evening to some of you joining on our virtual platform. It is a great honor to be standing before
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |